PHARMING GROUP NV (PHGN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:PHGN - NL0010391025 - Common Stock
1.442 EUR
+0.09 (+7.05%)
Overall PHGN gets a fundamental rating of 5 out of 10. We evaluated PHGN against 83 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHGN get a neutral evaluation. Nothing too spectacular is happening here. PHGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHGN had negative earnings in the past year.
In the past year PHGN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PHGN reported negative net income in multiple years.
In multiple years PHGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
PHGN has a Return On Assets of 0.02%. This is in the better half of the industry: PHGN outperforms 68.67% of its industry peers.
PHGN has a Return On Equity of 0.04%. This is in the better half of the industry: PHGN outperforms 73.49% of its industry peers.
The Return On Invested Capital of PHGN (6.70%) is better than 80.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | 6.7% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 0.03%, PHGN is doing good in the industry, outperforming 71.08% of the companies in the same industry.
PHGN has a better Operating Margin (10.15%) than 77.11% of its industry peers.
The Gross Margin of PHGN (89.90%) is better than 83.13% of its industry peers.
In the last couple of years the Gross Margin of PHGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PHGN is creating some value.
Compared to 1 year ago, PHGN has more shares outstanding
Compared to 5 years ago, PHGN has more shares outstanding
Compared to 1 year ago, PHGN has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.09, we must say that PHGN is in the distress zone and has some risk of bankruptcy.
PHGN has a Altman-Z score (1.09) which is in line with its industry peers.
The Debt to FCF ratio of PHGN is 2.49, which is a good value as it means it would take PHGN, 2.49 years of fcf income to pay off all of its debts.
PHGN's Debt to FCF ratio of 2.49 is amongst the best of the industry. PHGN outperforms 83.13% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that PHGN is not too dependend on debt financing.
PHGN has a Debt to Equity ratio (0.46) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 1.09 |
ROIC/WACC1.24
WACC5.39%
2.3 Liquidity
PHGN has a Current Ratio of 3.16. This indicates that PHGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.16, PHGN is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
A Quick Ratio of 2.40 indicates that PHGN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.40, PHGN is in line with its industry, outperforming 56.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 96.30% over the past year.
Looking at the last year, PHGN shows a very strong growth in Revenue. The Revenue has grown by 26.78%.
PHGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
Based on estimates for the next years, PHGN will show a very strong growth in Earnings Per Share. The EPS will grow by 53.48% on average per year.
The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y287.06%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue Next Year25.91%
Revenue Next 2Y15.98%
Revenue Next 3Y13.26%
Revenue Next 5Y8.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Forward Earnings ratio is 42.76, which means the current valuation is very expensive for PHGN.
Based on the Price/Forward Earnings ratio, PHGN is valued a bit cheaper than 75.90% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, PHGN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHGN indicates a rather cheap valuation: PHGN is cheaper than 97.59% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PHGN is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.19 | ||
| EV/EBITDA | 0.88 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHGN's earnings are expected to grow with 59.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.54%
EPS Next 3Y59.38%
5. Dividend
5.1 Amount
No dividends for PHGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHGN (12/8/2025, 7:00:00 PM)
1.442
+0.09 (+7.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.01%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap98.80M
Revenue(TTM)362.27M
Net Income(TTM)100.00K
Analysts88.57
Price Target2.01 (39.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.76 | ||
| P/S | 0.32 | ||
| P/FCF | 2.19 | ||
| P/OCF | 2.16 | ||
| P/B | 0.43 | ||
| P/tB | 0.89 | ||
| EV/EBITDA | 0.88 |
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.34%
FCF(TTM)0.66
FCFY45.65%
OCF(TTM)0.67
OCFY46.2%
SpS4.54
BVpS3.32
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | 9.52% | ||
| ROIC | 6.7% | ||
| ROICexc | 11.77% | ||
| ROICexgc | 30.51% | ||
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% | ||
| FCFM | 14.51% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 4.03% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 6 | ||
| Cash Conversion | 101.53% | ||
| Profit Quality | 52570% | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | 1.09 |
F-Score7
WACC5.39%
ROIC/WACC1.24
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y287.06%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year25.91%
Revenue Next 2Y15.98%
Revenue Next 3Y13.26%
Revenue Next 5Y8.97%
EBIT growth 1Y357.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year375.55%
EBIT Next 3Y109.82%
EBIT Next 5Y78.86%
FCF growth 1Y309.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV / PHGN.DE FAQ
What is the fundamental rating for PHGN stock?
ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE.
What is the valuation status of PHARMING GROUP NV (PHGN.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHGN.DE). This can be considered as Fairly Valued.
What is the profitability of PHGN stock?
PHARMING GROUP NV (PHGN.DE) has a profitability rating of 5 / 10.